17 Mayıs 2012 Perşembe

Diabetes mellitus

To contact us Click HERE
Diabetes mellitus (DM), often simply referred to as diabetes, is a group of metabolic diseases in which your blood glucose, or sugar, levels are too high. Glucose comes from the foods you eat.  Insulin is a hormone that helps the glucose get into your cells to give them energy.  With Type 1 diabetes, your body does not make insulin.  With Type 2 diabetes, the more common type, your body does not make or use insulin well. Without enough insulin, the glucose stays in your blood.  This high blood sugar produces the classical symptoms of polyuria (frequent urination), polydipsia (increased thirst) and polyphagia (increased hunger).

Diabetes is a disease.  Over time, having too much glucose in your blood can cause serious problems.  It can damage your eyes, kidneys, and nerves.  Diabetes can also cause heart disease, stroke and even the need to remove a limb. Pregnant women can also get diabetes, called gestational diabetes.

A blood test can show if you have diabetes.  Exercise, weight control and sticking to your meal plan can help control your diabetes. You should also monitor your glucose level and take medicine if prescribed.

The Three Main Types of Diabetes mellitus are:

  • Type 1 Diabetes mellitus results from the body's failure to produce insulin, and presently requires the person to inject insulin. (Also referred to as insulin-dependent diabetes mellitus (IDDM) or "juvenile" diabetes).
  • Type 2 Diabetes mellitus results from insulin resistance, a condition in which cells fail to use insulin properly, sometimes combined with an absolute insulin deficiency. (Formerly referred to as noninsulin-dependent diabetes mellitus (NIDDM) or "adult-onset" diabetes).
  • Gestational diabetes is when pregnant women, who have never had diabetes before, have a high blood glucose level during pregnancy. It may precede development of type 2 DM.

Other forms of diabetes mellitus include congenital diabetes, which is due to genetic defects of insulin secretion, cystic fibrosis-related diabetes, steroid diabetes induced by high doses of glucocorticoids, and several forms of monogenic diabetes.

All forms of diabetes have been treatable since insulin became available in 1921, and type 2 diabetes may be controlled with medications. Both types 1 and 2 diabetes mellitus are chronic conditions that usually cannot be cured. Pancreas transplants have been tried with limited success in type 1 DM; gastric bypass surgery has been successful in many with morbid obesity and type 2 DM. Gestational diabetes usually resolves after delivery. Diabetes without proper treatments can cause many complications. Acute complications include hypoglycemia, diabetic ketoacidosis, or nonketotic hyperosmolar coma. Serious long-term complications include cardiovascular disease, chronic renal failure, and diabetic retinopathy (retinal damage). Adequate treatment of diabetes is thus important, as well as blood pressure control and lifestyle factors such as smoking cessation and maintaining a healthy body weight.

Globally as of 2010, an estimated 285 million people have type 2 diabetes, making up about 90% of all diabetes cases.

Classification

Comparison of type 1 and 2 diabetes

Feature                                                          Type 1 diabetes                 Type 2 diabetes
Onset                                                             Sudden                             Gradual
Age at onset                                                  Mostly in children              Mostly in adults
Body habitus                                                 Thin or normal                   Often obese
Ketoacidosis                                                 Common                            Rare
Autoantibodies                                              Usually present                   Absent
Endogenous insulin                                      Low or absent                     Normal, decreased or increased
Concordance in identical twins                    50%                                    90%
Prevalence                                                   ~10%                                  ~90%



Diabetes mellitus is classified into four broad categories: type 1, type 2, gestational diabetes and "other types" ("other types of diabetes result from specific genetic conditions such as maturity-onset diabetes of youth, surgery, medications, infections, pancreatic disease, and other illnesses.  Such types of diabetes account for 1% to 5% of all diagnosed cases").  The term "diabetes", without qualification, usually refers to diabetes mellitus. The rare disease diabetes insipidus has similar symptoms as diabetes mellitus type 1 and type 2, but is unrelated.

The term "type 1 diabetes" has replaced several former terms, including childhood-onset diabetes, juvenile diabetes, and insulin-dependent diabetes mellitus (IDDM). Likewise, the term "type 2 diabetes" has replaced several former terms, including adult-onset diabetes, obesity-related diabetes, and noninsulin-dependent diabetes mellitus (NIDDM). Beyond these two types, there is no agreed-upon standard nomenclature. Various sources have defined "type 3 diabetes" as: gestational diabetes, insulin-resistant type 1 diabetes (or "double diabetes"), type 2 diabetes which has progressed to require injected insulin, and latent autoimmune diabetes of adults (or LADA or "type 1.5" diabetes).

Diabetes mellitus type 1

Type 1 diabetes mellitus is characterized by loss of the insulin-producing beta cells of the islets of Langerhans in the pancreas, leading to insulin deficiency.  This type can be further classified as immune-mediated or idiopathic. The majority of type 1 diabetes is of the immune-mediated nature, in which beta cell loss is a T-cell-mediated autoimmune attack.  There is no known preventive measure against type 1 diabetes, which causes approximately 10% of DM cases in North America and Europe. Most affected people are otherwise healthy and of a healthy weight when onset occurs. Sensitivity and responsiveness to insulin are usually normal, especially in the early stages. Type 1 diabetes can affect children or adults, but was traditionally termed "juvenile diabetes" because a majority of these diabetes cases were in children.

"Brittle" diabetes, also known as unstable diabetes or labile diabetes, is a term that was traditionally used to describe to dramatic and recurrent swings in glucose levels, often occurring for no apparent reason in insulin-dependent diabetes. This term, however, has no biologic basis and should not be used.  There are many different reasons for type 1 diabetes to be accompanied by "irregular and unpredictable hyperglycemias, frequently with ketosis", and sometimes serious hypoglycemias, including an impaired counterregulatory response to hypoglycemia, occult infection, gastroparesis (which leads to erratic absorption of dietary carbohydrates), and endocrinopathies (e.g., Addison's disease).  These phenomena are believed to occur no more frequently than in 1% to 2% of persons with type 1 diabetes.

Diabetes mellitus type 2

Type 2 diabetes mellitus is characterized by insulin resistance, which may be combined with relatively reduced insulin secretion.  The defective responsiveness of body tissues to insulin is believed to involve the insulin receptor. However, the specific defects are not known. Diabetes mellitus cases due to a known defect are classified separately. Type 2 diabetes is the most common type.  In the early stage of type 2, the predominant abnormality is reduced insulin sensitivity. At this stage, hyperglycemia can be reversed by a variety of measures and medications that improve insulin sensitivity or reduce glucose production by the liver.

Gestational Diabetes mellitus (GDM)

Gestational diabetes resembles type 2 diabetes in several respects, involving a combination of relatively inadequate insulin secretion and responsiveness.  It occurs in about 2%–5% of all pregnancies and may improve or disappear after delivery.  Gestational diabetes is fully treatable, but requires careful medical supervision throughout the pregnancy.  About 20%–50% of affected women develop type 2 diabetes later in life.

Though it may be transient, untreated gestational diabetes can damage the health of the fetus or mother. Risks to the baby include macrosomia (high birth weight), congenital cardiac and central nervous system anomalies, and skeletal muscle malformations. Increased fetal insulin may inhibit fetal surfactant production and cause respiratory distress syndrome.  Hyperbilirubinemia may result from red blood cell destruction.  In severe cases, perinatal death may occur, most commonly as a result of poor placental perfusion due to vascular impairment.  Labor induction may be indicated with decreased placental function.  A Caesarean section may be performed if there is marked fetal distress or an increased risk of injury associated with macrosomia, such as shoulder dystocia.

A 2008 study completed in the U.S. found the number of American women entering pregnancy with pre-existing diabetes is increasing. In fact, the rate of diabetes in expectant mothers has more than doubled in the past six years.  This is particularly problematic as diabetes raises the risk of complications during pregnancy, as well as increasing the potential for the children of diabetic mothers to become diabetic in the future.

Other Types

Prediabetes indicates a condition that occurs when a person's blood glucose levels are higher than normal but not high enough for a diagnosis of type 2 DM.  Many people destined to develop type 2 DM spend many years in a state of prediabetes which has been termed "America's largest healthcare epidemic".

Latent autoimmune diabetes of adults (LADA) is a condition in which type 1 DM develops in adults. Adults with LADA are frequently initially misdiagnosed as having type 2 DM, based on age rather than etiology.

Some cases of diabetes are caused by the body's tissue receptors not responding to insulin (even when insulin levels are normal, which is what separates it from type 2 diabetes); this form is very uncommon. Genetic mutations (autosomal or mitochondrial) can lead to defects in beta cell function. Abnormal insulin action may also have been genetically determined in some cases. Any disease that causes extensive damage to the pancreas may lead to diabetes (for example, chronic pancreatitis and cystic fibrosis). Diseases associated with excessive secretion of insulin-antagonistic hormones can cause diabetes (which is typically resolved once the hormone excess is removed). Many drugs impair insulin secretion and some toxins damage pancreatic beta cells. The ICD-10 (1992) diagnostic entity, malnutrition-related diabetes mellitus (MRDM or MMDM, ICD-10 code E12), was deprecated by the World Health Organization (WHO) when the current taxonomy was introduced in 1999.

Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications (World Health Organization)

Signs and Symptoms

The classical symptoms of diabetes are polyuria (frequent urination), polydipsia (increased thirst) and polyphagia (increased hunger).  Symptoms may develop rapidly (weeks or months) in type 1 diabetes, while they usually develop much more slowly and may be subtle or absent in type 2 diabetes.

Overview of the most significant symptoms of diabetes.

Prolonged high blood glucose can cause glucose absorption in the lens of the eye, which leads to changes in its shape, resulting in vision changes. Blurred vision is a common complaint leading to a diabetes diagnosis; type 1 should always be suspected in cases of rapid vision change, whereas with type 2 change is generally more gradual, but should still be suspected.  A number of skin rashes which can occur in diabetes are collectively known as diabetic dermadromes.

Diabetic Emergencies

People (usually with type 1 diabetes) may also present with diabetic ketoacidosis, a state of metabolic dysregulation characterized by the smell of acetone, a rapid, deep breathing known as Kussmaul breathing, nausea, vomiting and abdominal pain, and altered states of consciousness.  A rare but equally severe possibility is hyperosmolar nonketotic state, which is more common in type 2 diabetes and is mainly the result of dehydration.
Complications Diabetes mellitus
All forms of diabetes increase the risk of long-term complications. These typically develop after many years (10–20), but may be the first symptom in those who have otherwise not received a diagnosis before that time. The major long-term complications relate to damage to blood vessels.  Diabetes doubles the risk of cardiovascular disease.  The main "macrovascular" diseases (related to atherosclerosis of larger arteries) are ischemic heart disease (angina and myocardial infarction), stroke, and peripheral vascular disease.

Diabetes also causes "microvascular events"—damage to the small blood vessels.  Diabetic retinopathy, which affects blood vessel formation in the retina of the eye, can lead to visual symptoms, reduced vision, and potentially blindness.  Diabetic nephropathy, the impact of diabetes on the kidneys, can lead to scarring changes in the kidney tissue, loss of small or progressively larger amounts of protein in the urine, and eventually chronic kidney disease requiring dialysis.  Diabetic neuropathy is the impact of diabetes on the nervous system, most commonly causing numbness, tingling and pain in the feet and also increasing the risk of skin damage due to altered sensation. Together with vascular disease in the legs, neuropathy contributes to the risk of diabetes-related foot problems (such as diabetic foot ulcers) that can be difficult to treat and occasionally require amputation.

Causes

The cause of diabetes depends on the type.

Type 1 diabetes is partly inherited, and then triggered by certain infections, with some evidence pointing at Coxsackie B4 virus. A genetic element in individual susceptibility to some of these triggers has been traced to particular HLA genotypes (i.e., the genetic "self" identifiers relied upon by the immune system). However, even in those who have inherited the susceptibility, type 1 DM seems to require an environmental trigger.

Type 2 diabetes is due primarily to lifestyle factors and genetics.

The following is a comprehensive list of other causes of diabetes:

  • Genetic defects of β-cell function
    • Maturity onset diabetes of the young
    • Mitochondrial DNA mutations
  • Genetic defects in insulin processing or insulin action
    • Defects in proinsulin conversion
    • Insulin gene mutations
    • Insulin receptor mutations
  • Exocrine pancreatic defects
    • Chronic pancreatitis
    • Pancreatectomy
    • Pancreatic neoplasia
    • Cystic fibrosis
    • Hemochromatosis
    • Fibrocalculous pancreatopathy
  • Endocrinopathies
    • Growth hormone excess (acromegaly)
    • Cushing syndrome
    • Hyperthyroidism
    • Pheochromocytoma
    • Glucagonoma
  • Infections
    • Cytomegalovirus infection
    • Coxsackievirus B
  • Drugs
    • Glucocorticoids
    • Thyroid hormone
    • β-adrenergic agonists
    • Statins


Pathophysiology

Insulin is the principal hormone that regulates uptake of glucose from the blood into most cells (primarily muscle and fat cells, but not central nervous system cells). Therefore, deficiency of insulin or the insensitivity of its receptors plays a central role in all forms of diabetes mellitus.

The fluctuation of blood sugar (red) and the sugar-lowering hormone insulin (blue) in humans during the course of a day with three meals - one of the effects of a sugar-rich vs a starch-rich meal is highlighted.


Humans are capable of digesting some carbohydrates, in particular those most common in food; starch, and some disaccharides such as sucrose, are converted within a few hours to simpler forms, most notably the monosaccharide glucose, the principal carbohydrate energy source used by the body.  The rest are passed on for processing by gut flora largely in the colon.  Insulin is released into the blood by beta cells (β-cells), found in the islets of Langerhans in the pancreas, in response to rising levels of blood glucose, typically after eating. Insulin is used by about two-thirds of the body's cells to absorb glucose from the blood for use as fuel, for conversion to other needed molecules, or for storage.

Insulin is also the principal control signal for conversion of glucose to glycogen for internal storage in liver and muscle cells. Lowered glucose levels result both in the reduced release of insulin from the β-cells and in the reverse conversion of glycogen to glucose when glucose levels fall. This is mainly controlled by the hormone glucagon, which acts in the opposite manner to insulin. Glucose thus forcibly produced from internal liver cell stores (as glycogen) re-enters the bloodstream; muscle cells lack the necessary export mechanism. Normally, liver cells do this when the level of insulin is low (which normally correlates with low levels of blood glucose).

Higher insulin levels increase some anabolic ("building up") processes, such as cell growth and duplication, protein synthesis, and fat storage. Insulin (or its lack) is the principal signal in converting many of the bidirectional processes of metabolism from a catabolic to an anabolic direction, and vice versa. In particular, a low insulin level is the trigger for entering or leaving ketosis (the fat-burning metabolic phase).

If the amount of insulin available is insufficient, if cells respond poorly to the effects of insulin (insulin insensitivity or resistance), or if the insulin itself is defective, then glucose will not have its usual effect, so it will not be absorbed properly by those body cells that require it, nor will it be stored appropriately in the liver and muscles. The net effect is persistent high levels of blood glucose, poor protein synthesis, and other metabolic derangements, such as acidosis.

When the glucose concentration in the blood is raised beyond its renal threshold (about 10 mmol/L, although this may be altered in certain conditions, such as pregnancy), reabsorption of glucose in the proximal renal tubuli is incomplete, and part of the glucose remains in the urine (glycosuria). This increases the osmotic pressure of the urine and inhibits reabsorption of water by the kidney, resulting in increased urine production (polyuria) and increased fluid loss. Lost blood volume will be replaced osmotically from water held in body cells and other body compartments, causing dehydration and increased thirst.

Diagnosis

Diabetes diagnostic criteria

Condition                                    2 hour glucose             Fasting glucose                                  HbA1c 
                                                   mmol/l(mg/dl)               mmol/l(mg/dl)                                       %
Normal                                        <7.8 (<140)                 <6.1 (<110)                                             <6.0
Impaired fasting glycaemia        <7.8 (<140)                  ≥ 6.1(≥110) & <7.0(<126)                         6.0-6.4
Impaired glucose tolerance        ≥7.8 (≥140)                  <7.0 (<126)                                              6.0-6.4
Diabetes mellitus                       ≥11.1 (≥200)                 ≥7.0 (≥126)                                               ≥6.5


Diabetes mellitus is characterized by recurrent or persistent hyperglycemia, and is diagnosed by demonstrating any one of the following:

  • Fasting plasma glucose level ≥ 7.0 mmol/l (126 mg/dl)
  • Plasma glucose ≥ 11.1 mmol/l (200 mg/dL) two hours after a 75 g oral glucose load as in a glucose tolerance test
  • Symptoms of hyperglycemia and casual plasma glucose ≥ 11.1 mmol/l (200 mg/dl)
  • Glycated hemoglobin (Hb A1C) ≥ 6.5%[21]

A positive result, in the absence of unequivocal "hyperglycemia", should be confirmed by a repeat of any of the above methods on a different day. It is preferable to measure a fasting glucose level because of the ease of measurement and the considerable time commitment of formal glucose tolerance testing, which takes two hours to complete and offers no prognostic advantage over the fasting test.  According to the current definition, two fasting glucose measurements above 126 mg/dl (7.0 mmol/l) is considered diagnostic for diabetes mellitus.

People with fasting glucose levels from 110 to 125 mg/dl (6.1 to 6.9 mmol/l) are considered to have impaired fasting glucose.  Patients with plasma glucose at or above 140 mg/dL (7.8 mmol/L), but not over 200 mg/dL (11.1 mmol/L), two hours after a 75 g oral glucose load are considered to have impaired glucose tolerance. Of these two prediabetic states, the latter in particular is a major risk factor for progression to full-blown diabetes mellitus, as well as cardiovascular disease.  Glycated hemoglobin is better than fasting glucose for determining risks of cardiovascular disease and death from any cause.

Management: Diabetes management
Diabetes mellitus is a chronic disease which cannot be cured except in very specific situations. Management concentrates on keeping blood sugar levels as close to normal ("euglycemia") as possible, without causing hypoglycemia. This can usually be accomplished with diet, exercise, and use of appropriate medications (insulin in the case of type 1 diabetes, oral medications, as well as possibly insulin, in type 2 diabetes).

Patient education, understanding, and participation is vital, since the complications of diabetes are far less common and less severe in people who have well-managed blood sugar levels.  The goal of treatment is an HbA1C level of 6.5%, but should not be lower than that, and may be set higher.  Attention is also paid to other health problems that may accelerate the deleterious effects of diabetes. These include smoking, elevated cholesterol levels, obesity, high blood pressure, and lack of regular exercise.

Type 2 diabetes: the management of type 2 diabetes (update) Clinical guidelines, CG66

Lifestyle

There are roles for patient education, dietetic support, sensible exercise, with the goal of keeping both short-term and long-term blood glucose levels within acceptable bounds. In addition, given the associated higher risks of cardiovascular disease, lifestyle modifications are recommended to control blood pressure.

Medications
Oral medications

Metformin® is generally considered as a first-line treatment for type 2 diabetes, as there is good evidence that it decreases mortality.  Routine use of aspirin®, however, has not been found to improve outcomes in uncomplicated diabetes.

Insulin therapy

Type 1 diabetes is typically treated with a combinations of regular and NPH insulin, or synthetic insulin analogs. When insulin is used in type 2 diabetes, a long-acting formulation is usually added initially, while continuing oral medications.  Doses of insulin are then increased to effect.

Support

In countries using a general practitioner system, such as the United Kingdom, care may take place mainly outside hospitals, with hospital-based specialist care used only in case of complications, difficult blood sugar control, or research projects. In other circumstances, general practitioners and specialists share care of a patient in a team approach. Optometrists, podiatrists/chiropodists, dietitians, physiotherapists, nursing specialists (e.g., diabetic specialist nurses), nurse practitioners, or certified diabetes educators, may jointly provide multidisciplinary expertise.  Home telehealth support can be an effective management technique.

Epidemiology

Globally, as of 2010, an estimated 285 million people had diabetes, with type 2 making up about 90% of the cases.  Its incidence is increasing rapidly, and by 2030, this number is estimated to almost double.  Diabetes mellitus occurs throughout the world, but is more common (especially type 2) in the more developed countries. The greatest increase in prevalence is, however, expected to occur in "the urban population in developing countries", where most patients will probably be found by 2030.  The increase in incidence in developing countries follows the trend of urbanization and lifestyle changes, perhaps most importantly a "Western-style" diet. This has suggested an environmental (i.e., dietary) effect, but there is little understanding of the mechanism(s) at present, though there is much speculation, some of it most compellingly presented.

United States

For at least 20 years, diabetes rates in Americans have been increasing substantially. In 2010, nearly 26 million people have diabetes in the United States alone, from those 7 million people remain undiagnosed. Another 57 million people are estimated to have pre-diabetes.

Total Prevalence of Diabetes and Pre-diabetes

The Centers for Disease Control has termed the change "a major public health threat of epidemic proportions".  The National Diabetes Information Clearinghouse estimates diabetes costs $132 billion in the United States alone every year. About 5%–10% of diabetes cases in North America are type 1, with the rest being type 2. The fraction of type 1 in other parts of the world differs. Most of this difference is not currently understood. The American Diabetes Association (ADA) cites the 2003 assessment of the National Center for Chronic Disease Prevention and Health Promotion (Centers for Disease Control and Prevention) that "for Americans born after 2000 the lifetime probability of being diagnosed with diabetes mellitus is substantial".

According to the American Diabetes Association (ADA), about 18.3% (8.6 million) of Americans age 60 and older have been diagnosed with diabetes.  Diabetes mellitus prevalence increases with age, and the numbers of older persons with diabetes are expected to grow as the elderly population increases in number. The Third National Health and Nutrition Examination Survey, 1988-1994 (NHANES III) demonstrated, in the population over 65 years old, 18% to 20% have diabetes, with 40% having either diabetes or its precursor form of impaired glucose tolerance.

Australia

Indigenous populations in first world countries have a higher prevalence and increasing incidence of diabetes than their corresponding nonindigenous populations. In Australia, the age-standardized prevalence of self-reported diabetes in indigenous Australians is almost four times that of nonindigenous Australians.  Preventative community health programs, such as Sugar Man (diabetes education), are showing some success in tackling this problem.

United Kingdom

About 3.8 million people in the United Kingdom have diabetes mellitus, but the charity Diabetes U.K. have made predictions that that could become high as 6.2 million by 2035/2036. Diabetes U.K. have also predicted that the National Health Service (NHS) could be spending as much as £16.9 billion on diabetes mellitus by 2035, a figure that means that the NHS could be spending as much as 17% of its budget on diabetes treatment by 2035.

History of Diabetes
Diabetes was one of the first diseases described, with an Egyptian manuscript from c. 1500 BCE mentioning “too great emptying of the urine”.  The first described cases are believed to be of type 1 diabetes.  Indian physicians around the same time identified the disease and classified it as madhumeha or "honey urine", noting the urine would attract ants.  The term "diabetes" or "to pass through" was first used in 230 BCE by the Greek Appollonius of Memphis.  The disease was rare during the time of the Roman empire, with Galen commenting he had only seen two cases during his career.  Type 1 and type 2 diabetes where identified as separate conditions for the first time by the Indian physicians Sushruta and Charaka in 400-500 AD with type 1 associated with youth and type 2 with being overweight.  The term "mellitus" or "from honey" was added by the Briton John Rolle in the late 1700s to separate the condition from diabetes insipidus, which is also associated with frequent urination.  While many measure where tried, effective treatment was not developed until the early part of the 20th century, when Canadians Frederick Banting and Charles Best developed insulin in 1921 and 1922.  This was followed by the development of the long-acting insulin NPH in the 1940s.

Etymology

The word diabetes ( /ËŒdaɪ.əˈbiË�tiË�z/ or /ËŒdaɪ.əˈbiË�tɨs/) comes from Latin diabÄ“tÄ“s, which in turn comes from Ancient Greek διαβήτης (diabÄ“tÄ“s) which literally means "a passer-through; siphon".  Ancient Greek physician Aretaeus of Cappadocia (fl. 1st century CE) used that word, with the intended meaning "excessive discharge of urine", as the name for the disease.  Ultimately, the word comes from Greek διαβαίνειν (diabainein), meaning "to pass through", which is composed of δια- (dia-), meaning "through" and βαίνειν (bainein), meaning "to go".  The word "diabetes" is first recorded in English, in the form diabete, in a medical text written around 1425.

The word mellitus (/mɨˈlaɪtÉ™s/ or /ˈmÉ›lɨtÉ™s/) comes from the classical Latin word mellÄ«tus, meaning "mellite" (i.e. sweetened with honey; honey-sweet). The Latin word comes from mell-, which comes from mel, meaning "honey"; sweetness; pleasant thing, and the suffix -Ä«tus, whose meaning is the same as that of the English suffix "-ite".  It was Thomas Willis who in 1675 added "mellitus" to the word "diabetes" as a designation for the disease, when he noticed the urine of a diabetic had a sweet taste (glycosuria).  This sweet taste had been noticed in urine by the ancient Greeks, Chinese, Egyptians, Indians, and Persians.

Society and Culture

The 1990 the "St. Vincent Declaration" was the result of international efforts to improve the care accorded to those with diabetes. Doing so is important not only in terms of quality of life and life expectancy, but also economically—expenses due to diabetes have been shown to be a major drain on health- and productivity-related resources for healthcare systems and governments.  Several countries established more and less successful national diabetes programmes to improve treatment of the disease.  People in the US workforce who have diabetes with neuropathic symptoms "lose the equivalent of $3.65 billion per year in health-related lost productive time (LPT)".

In Other Animals: Diabetes mellitus in dogs and cats

In animals, diabetes is most commonly encountered in dogs and cats. Middle-aged animals are most commonly affected. Female dogs are twice as likely to be affected as males, while according to some sources, male cats are also more prone than females. In both species, all breeds may be affected, but some small dog breeds are particularly likely to develop diabetes, such as miniature poodles.  The symptoms may relate to fluid loss and polyuria, but the course may also be insidious. Diabetic animals are more prone to infections. The long-term complications recognized in humans are much rarer in animals. The principles of treatment (weight loss, oral antidiabetics, subcutaneous insulin) and management of emergencies (e.g. ketoacidosis) are similar to those in humans.


External Links
I Have Diabetes - National Diabetes Education Program.
Introduction to Diabetes - National Institute of Diabetes and Digestive and Kidney Diseases.
JAMA Patient Page: Diabetes - American Medical Association. - PDF.

Diagnosis/Symptoms

A1C Test and Diabetes - National Institute of Diabetes and Digestive and Kidney Diseases.
Diabetes Tests - American Association for Clinical Chemistry.
Diagnosis of Diabetes - National Institute of Diabetes and Digestive and Kidney Diseases.
Glucose Tests - American Association for Clinical Chemistry.
Microalbumin Test - Mayo Foundation for Medical Education and Research.

Treatment

Treatments - National Institute of Diabetes and Digestive and Kidney Diseases.

Prevention/Screening

Am I at Risk for Type 2 Diabetes? - National Institute of Diabetes and Digestive and Kidney Diseases.

Get Real: You Don't Have to Knock Yourself Out to Prevent Diabetes - National Diabetes Education Program - PDF.
More Than 50 Ways to Prevent Diabetes - National Diabetes Education Program - PDF.
Take Steps to Prevent Type 2 Diabetes - Office of Disease Prevention and Health Promotion.
Your Game Plan for Preventing Type 2 Diabetes - National Diabetes Education Program - PDF.
Your Game Plan to Prevent Type 2 Diabetes: Fat and Calorie Counter - National Diabetes Education Program - PDF.

Complementary and Alternative Medicine (CAM) Therapy

Complementary and Alternative Medical Therapies for Diabetes - National Institute of Diabetes and Digestive and Kidney Diseases.

Coping

Anger - American Diabetes Association.
Help a Loved One with Diabetes - National Diabetes Education Program.
Stress - American Diabetes Association.

Disease Management

AADE7 Self-Care Behaviors Handouts - American Association of Diabetes Educators.
Blood Glucose Monitoring Devices - Food and Drug Administration.
Blood Sugar Testing: Why, When and How - Mayo Foundation for Medical Education and Research.
Checking for Ketones - American Diabetes Association.
Continuous Glucose Monitoring - National Institute of Diabetes and Digestive and Kidney Diseases.
Diabetes HealthSense: Resources for Living Well - National Diabetes Education Program.
Diabetes Management: How Lifestyle, Daily Routine Affect Blood Sugar - Mayo Foundation for Medical Education and Research.
Diabetes: Monitoring Your Blood Sugar Level - American Academy of Family Physicians.
Diabetes: Numbers at a Glance 2012 - National Diabetes Education Program - PDF.
Have Diabetes. Will Travel. - National Diabetes Education Program - PDF.
Managing Diabetes during the Holidays - Centers for Disease Control and Prevention.
Patient Guide to Continuous Glucose Monitoring - Hormone Foundation - PDF.
Tight Diabetes Control - American Diabetes Association.
Tips to Help You Stay Healthy - National Diabetes Education Program - PDF.
What I Need to Know about Physical Activity and Diabetes - National Institute of Diabetes and Digestive and Kidney Diseases.
Your First Doctor Visit - American Diabetes Association.
Your Glucose Meter - Food and Drug Administration.
Your Health Care Team - American Diabetes Association.

Specific Conditions

All about Insulin Resistance - American Diabetes Association - PDF.
Hyperinsulinemia: Is It Diabetes? - Mayo Foundation for Medical Education and Research.
Monogenic Diabetes - Hormone Foundation - PDF.

Health Check Tools

Check Your Risk for Developing Type 2 Diabetes - Centers for Disease Control and Prevention.

Tutorials

What is Diabetes? - National Institute of Diabetes and Digestive and Kidney Diseases.

Videos

Control Your Diabetes: It's Worth Your Time, Part 1: The Basics - Healthy Roads Media.
Control Your Diabetes: It's Worth Your Time, Part 2: Diet and Exercise - Healthy Roads Media.
Control Your Diabetes: It's Worth Your Time, Part 3: Medicines and Glucose Numbers - Healthy Roads Media.
Diabetes Movie - Nemours Foundation.
Diabetes Travel Tips Video - National Diabetes Education Program.
Healthy Coping - American Association of Diabetes Educators.
Healthy Eating at Family Gatherings and Special Events Video - National Diabetes Education Program.
If I Had - Diabetes - Insidermedicine.
If I Had - Pre-Diabetes - Insidermedicine.
Know Your Diabetes ABCs - National Institute of Diabetes and Digestive and Kidney Diseases.
Monitoring - American Association of Diabetes Educators.
Physical Activity: Practical Tips and Action Steps Video - National Diabetes Education Program.
What Happens in Diabetes? - Nemours Foundation.

Clinical Trials

ClinicalTrials.gov: Diabetes Mellitus - National Institutes of Health.

Genetics

The Genetic Landscape of Diabetes - National Center for Biotechnology Information.
Genetics Home Reference: 6q24-related transient neonatal diabetes mellitus - National Library of Medicine.
Genetics Home Reference: Berardinelli-Seip congenital lipodystrophy - National Library of Medicine.
Genetics Home Reference: Permanent neonatal diabetes mellitus - National Library of Medicine.
Genetics Home Reference: Thiamine-responsive megaloblastic anemia syndrome - National Library of Medicine.
Genetics Home Reference: Wolfram syndrome - National Library of Medicine.
Monogenic Forms of Diabetes: Neonatal Diabetes Mellitus and Maturity-onset Diabetes of the Young - National Diabetes Information Clearinghouse.

Research

Access: Diabetes Research - American Diabetes Association.
Case-Managed Care Improves Outcomes for Depressed Patients with Multiple Medical Conditions - National Institute of Mental Health.
Diabetes Prevention Program - National Diabetes Information Clearinghouse.
Peer Mentoring and Financial Incentives to Improve Glucose Control in African American Veterans - American College of Physicians - PDF.
Diabetes. Type 2 - National Institute of Diabetes and Digestive and Kidney Diseases.
Understanding Insulin Sensitivity and Diabetes - National Institutes of Health.
Years of Life Without Diabetes Decreasing - American Diabetes Association.

Directories

Directory of Diabetes Organizations - National Institute of Diabetes and Digestive and Kidney Diseases.
Find a Diabetes Educator - American Association of Diabetes Educators.

Organizations

American Diabetes Association.
National Diabetes Education Program.
National Diabetes Information Clearinghouse - National Institute of Diabetes and Digestive and Kidney Diseases.
National Institute of Diabetes and Digestive and Kidney Diseases.

Statistics

Diabetes by the Numbers: State-By-State Impact of Diabetes (data are for the US)- American Podiatric Medical Association.
FastStats: Diabetes (data are for the US)- National Center for Health Statistics.
National Diabetes Statistics, 2011 - National Institute of Diabetes and Digestive and Kidney Diseases.
Number of Americans with Diabetes Rises to Nearly 26 Million - National Institute of Diabetes and Digestive and Kidney Diseases.
Physical Inactivity Estimates, by County - Centers for Disease Control and Prevention.
Tuberculosis and Diabetes - World Health Organization - PDF.

Children

Eagle Books: Stories about Growing Strong and Preventing Diabetes - Centers for Disease Control and Prevention.
The Eagle's Nest - Centers for Disease Control and Prevention.
For Parents and Kids - American Diabetes Association.
How Is Diabetes Treated in Children? - US Food and Drug Administration.
Overview of Diabetes in Children and Adolescents - National Diabetes Education Program. - PDF.
Welcome to. Planet D - American Diabetes Association.
When Your Child Is Diagnosed with Diabetes: Parents' Questions for the Health Care Team - National Diabetes Education Program.

Teenagers

Living with Diabetes: Driving - American Diabetes Association.
Living with Diabetes: Dating - American Diabetes Association.
Living with Diabetes: Teens and Parties - American Diabetes Association.
Quiz for Teens with Diabetes - National Diabetes Education Program.
Tips for Teens with Diabetes: Be Active - National Diabetes Education Program.
Tips for Teens with Diabetes: Dealing with the Ups and Downs of Diabetes - National Diabetes Education Program.
Tips for Teens with Diabetes: What Is Diabetes? - National Diabetes Education Program - PDF.
Transitions: From Pediatric to Adult Health Care - National Diabetes Education Program.

Men

Living with Diabetes: Men's Health - American Diabetes Association.

Women

Diabetes fact sheet - Dept. of Health and Human Services, Office on Women's Health.
Diabetes - US Food and Drug Administration.

Seniors

Diabetes in Older People - A Disease You Can Manage - National Institute on Aging.
Diabetes: What is Diabetes? - National Institute of Diabetes and Digestive and Kidney Diseases.


References

Shoback, edited by David G. Gardner, Dolores (2011). Greenspan's basic & clinical endocrinology (9th ed.). New York: McGraw-Hill Medical. pp. Chapter 17. ISBN 0071622438.
Williams textbook of endocrinology (12th ed.). Philadelphia: Elsevier/Saunders. pp. 1371–1435. ISBN 978-1-4377-0324-5.
Lambert, P.; Bingley, P. J. (2002). "What is Type 1 Diabetes?". Medicine 30: 1–5. doi:10.1383/medc.30.1.1.28264. Diabetes Symptoms.
"Diseases: Johns Hopkins Autoimmune Disease Research Center". http://autoimmune.pathology.jhmi.edu/diseases.cfm?systemID=3&DiseaseID=23. Retrieved 2007-09-23.
Rother KI (April 2007). "Diabetes treatment—bridging the divide". The New England Journal of Medicine 356 (15): 1499–501. doi:10.1056/NEJMp078030. PMID 17429082.
"Diabetes Mellitus (DM): Diabetes Mellitus and Disorders of Carbohydrate Metabolism: Merck Manual Professional". Merck.com. http://www.merck.com/mmpe/sec12/ch158/ch158b.html#sec12-ch158-ch158b-1206. Retrieved 2010-07-30.
Dorner M, Pinget M, Brogard JM (May 1977). "Essential labile diabetes" (in German). MMW Munch Med Wochenschr 119 (19): 671–4. PMID 406527.
Lawrence JM, Contreras R, Chen W, Sacks DA (May 2008). "Trends in the prevalence of preexisting diabetes and gestational diabetes mellitus among a racially/ethnically diverse population of pregnant women, 1999–2005". Diabetes Care 31 (5): 899–904. doi:10.2337/dc07-2345. PMID 18223030.
Handelsman Yehuda, MD. "A Doctor's Diagnosis: Prediabetes". Power of Prevention 1 (2): 2009.
World Health Organisation Department of Noncommunicable Disease Surveillance (1999). "Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications" (PDF). http://whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf.
Cooke DW, Plotnick L (November 2008). "Type 1 diabetes mellitus in pediatrics". Pediatr Rev 29 (11): 374–84; quiz 385. doi:10.1542/pir.29-11-374. PMID 18977856.
"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies : The Lancet". http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2960484-9/fulltext.
Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M et al (2011). "Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials". BMJ 343: d4169. doi:10.1136/bmj.d4169. PMC 3144314. PMID 21791495.
Risérus U, Willett WC, Hu FB (January 2009). "Dietary fats and prevention of type 2 diabetes". Progress in Lipid Research 48 (1): 44–51. doi:10.1016/j.plipres.2008.10.002. PMC 2654180. PMID 19032965.
Unless otherwise specified, reference is: Table 20-5 in Mitchell, Richard Sheppard; Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson. Robbins Basic Pathology. Philadelphia: Saunders. ISBN 1-4160-2973-7. 8th edition.
Sattar, N; Preiss, D, Murray, HM, Welsh, P, Buckley, BM, de Craen, AJ, Seshasai, SR, McMurray, JJ, Freeman, DJ, Jukema, JW, Macfarlane, PW, Packard, CJ, Stott, DJ, Westendorp, RG, Shepherd, J, Davis, BR, Pressel, SL, Marchioli, R, Marfisi, RM, Maggioni, AP, Tavazzi, L, Tognoni, G, Kjekshus, J, Pedersen, TR, Cook, TJ, Gotto, AM, Clearfield, MB, Downs, JR, Nakamura, H, Ohashi, Y, Mizuno, K, Ray, KK, Ford, I (2010-02-27). "Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials". Lancet 375 (9716): 735–42. doi:10.1016/S0140-6736(09)61965-6. PMID 20167359.
"Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia" (pdf). World Health Organization. www.who.int. 2006. http://www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf. Retrieved 2011-02-20.
Vijan, S (2010 Mar 2). "Type 2 diabetes.". Annals of internal medicine 152 (5): ITC31-15; quiz ITC316. doi:10.1059/0003-4819-152-5-201003020-01003. PMID 20194231.
"Diabetes Care" January 2010". American Diabetes Association. http://care.diabetesjournals.org/content/33/Supplement_1/S3.full. Retrieved 2010-01-29.
Saydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL (August 2001). "Postchallenge hyperglycemia and mortality in a national sample of U.S. adults". Diabetes Care 24 (8): 1397–402. doi:10.2337/diacare.24.8.1397. PMID 11473076.
Santaguida PL, Balion C, Hunt D, Morrison K, Gerstein H, Raina P, Booker L, Yazdi H. "Diagnosis, Prognosis, and Treatment of Impaired Glucose Tolerance and Impaired Fasting Glucose". Summary of Evidence Report/Technology Assessment, No. 128. Agency for Healthcare Research and Quality. http://www.ahrq.gov/clinic/epcsums/impglusum.htm. Retrieved 2008-07-20.
Selvin E, Steffes MW, Zhu H et al (2010). "Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults". N. Engl. J. Med. 362 (9): 800–11. doi:10.1056/NEJMoa0908359. PMC 2872990. PMID 20200384.
Nathan DM, Cleary PA, Backlund JY et al (December 2005). "Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes". The New England Journal of Medicine 353 (25): 2643–53. doi:10.1056/NEJMoa052187. PMC 2637991. PMID 16371630.
(April 1995). "The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group". Annals of Internal Medicine 122 (8): 561–8. doi:10.1059/0003-4819-122-8-199504150-00001. PMID 7887548.
National Institute for Health and Clinical Excellence. Clinical guideline 66: Type 2 diabetes. London, 2008.
Adler AI, Stratton IM, Neil HA et al (August 2000). "Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study". BMJ 321 (7258): 412–9. doi:10.1136/bmj.321.7258.412. PMC 27455. PMID 10938049. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=27455. 
Ripsin, CM; Kang, H, Urban, RJ (2009-01-01). "Management of blood glucose in type 2 diabetes mellitus". American family physician 79 (1): 29–36. PMID 19145963. 
Pignone M, Alberts MJ, Colwell JA et al (June 2010). "Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation". Diabetes Care 33 (6): 1395–402. doi:10.2337/dc10-0555. PMC 2875463. PMID 20508233.
Polisena J, Tran K, Cimon K, Hutton B, McGill S, Palmer K (2009). "Home telehealth for diabetes management: a systematic review and meta-analysis". Diabetes Obes Metab 11 (10): 913–30. doi:10.1111/j.1463-1326.2009.01057.x. PMID 19531058. 
Wild, S; Roglic, G; Green, A; Sicree, R; King, H (2004). "Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030". Diabetes Care 27 (5): 1047–53. doi:10.2337/diacare.27.5.1047. PMID 15111519. 
http://www.cdc.gov/media/releases/2011/p0126_diabetes.html.
"CDC's Diabetes Program-News and Information-Press Releases-October 26, 2000". http://www.cdc.gov/Diabetes/news/docs/010126.htm. Retrieved 2008-06-23.
Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF (October 2003). "Lifetime risk for diabetes mellitus in the United States". JAMA 290 (14): 1884–90. doi:10.1001/jama.290.14.1884. PMID 14532317. 
American Diabetes Association (2005). "Total Prevalence of Diabetes & Pre-diabetes". Archived from the original on 2006-02-08. http://web.archive.org/web/20060208032127/http://www.diabetes.org/diabetes-statistics/prevalence.jsp. Retrieved 2006-03-17.
"Seniors and Diabetes". Elderly And Diabetes-Diabetes and Seniors. LifeMed Media. 2006. http://www.dlife.com/dLife/do/ShowContent/daily_living/seniors/. Retrieved 2007-05-14. 
Harris MI, Flegal KM, Cowie CC et al (April 1998). "Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994". Diabetes Care 21 (4): 518–24. doi:10.2337/diacare.21.4.518. PMID 9571335.
Australian Institute for Health and Welfare. "Diabetes, an overview". Archived from the original on 2008-06-17. http://web.archive.org/web/20080617222036/http://www.aihw.gov.au/indigenous/health/diabetes.cfm. Retrieved 2008-06-23. 
"NHS spending on diabetes 'to reach £16.9 billion by 2035'". 2012-04-25. http://www.diabetes.org.uk/About_us/News_Landing_Page/NHS-spending-on-diabetes-to-reach-169-billion-by-2035/. Retrieved 2012-04-26. 
Ripoll, Brian C. Leutholtz, Ignacio (2011-04-25). Exercise and disease management (2nd ed.). Boca Raton: CRC Press. pp. 25. ISBN 978-1-4398-2759-8. http://books.google.ca/books?id=eAn9-bm_pi8C&pg=PA25. 
Leonid Poretsky, (2009). Principles of diabetes mellitus (2nd ed.). New York: Springer. pp. 3. ISBN 978-0-387-09840-1. http://books.google.ca/books?id=i0qojvF1SpUC&pg=PA3.
Harper, Douglas (2001–2010). "Online Etymology Dictionary. diabetes". http://www.etymonline.com/index.php?search=diabetes&searchmode=none. Retrieved 2011-06-10.
Oxford English Dictionary. mellite. Retrieved 2011-06-10.
"MyEtimology. mellitus". http://www.myetymology.com/latin/mellitus.html. Retrieved 2011-06-10.
Oxford English Dictionary. -ite. Retrieved 2011-06-10.
Theodore H. Tulchinsky, Elena A. Varavikova (2008). The New Public Health, Second Edition. New York: Academic Press. p. 200. ISBN 0-12-370890-7. 
Piwernetz K, Home PD, Snorgaard O, Antsiferov M, Staehr-Johansen K, Krans M (May 1993). "Monitoring the targets of the St Vincent Declaration and the implementation of quality management in diabetes care: the DIABCARE initiative. The DIABCARE Monitoring Group of the St Vincent Declaration Steering Committee". Diabetic Medicine 10 (4): 371–7. doi:10.1111/j.1464-5491.1993.tb00083.x. PMID 8508624.
Stewart WF, Ricci JA, Chee E, Hirsch AG, Brandenburg NA (June 2007). "Lost productive time and costs due to diabetes and diabetic neuropathic pain in the US workforce". J. Occup. Environ. Med. 49 (6): 672–9. doi:10.1097/JOM.0b013e318065b83a. PMID 17563611.
"Diabetes mellitus". Merck Veterinary Manual, 9th edition (online version). 2005. http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/40302.htm. Retrieved 2011-10-23.


Content is in the public domain and may be reprinted, except if marked as copyrighted (©). Please credit Holistic Lifestyle Community Blog as the source. All copyrighted material is the property of its respective owners and may not be reprinted without their permission.

Holistic Lifestyle Community Blog has provided this material for information and education purposes only. It is not intended as a substitute for or to take the place of medical advice. We encourage you to discuss any decisions about your interest in, questions about, treatment or care, or the use of complementary and alternative medicine (CAM) and its therapies and what may be best for your overall health with a licensed health care provider (i.e. physician, registered dietician, pharmacist, etc.). The mention of any product, service, or therapy is not an endorsement by Holistic Lifestyle Community Blog. Any mention in the Holistic Lifestyle Community Blog of a specific brand name is not an endorsement of the product.

1 yorum:

  1. I was diagnose with genital warts since 2012 i have be taking lot treatment and all i got is outbreak. in 2015 I gave up the treatment because I can't continues wasting time and money on treatment at the end it will not cure me. about 6 weeks ago i did natural research online I had So many people talking good about natural remedy, after the research i was recommended to Dr onokun, And I wrote to him through his email and told him my problem after some conversations with him he gave me natural treatment after 1 week Dr onokun treated me i got cured permanently. and i went to see my doc he confirmed that the diseases has gone out from my body. every patients should know there is 100% natural hpv cure. contact Dr onokun his email address: dronokunherbalcure@gmail.com

    YanıtlaSil